Multiscale Mechanistic Modeling in Pharmaceutical Research and Development
- 18 November 2011
- book chapter
- Published by Springer Nature
- Vol. 736, 543-561
Abstract
Discontinuation of drug development projects due to lack of efficacy or adverse events is one of the main cost drivers in pharmaceutical research and development (R&D). Investments have to be written-off and contribute to the total costs of a successful drug candidate receiving marketing authorization and allowing return on invest. A vital risk for pharmaceutical innovator companies is late stage clinical failure since costs for individual clinical trials may exceed the one billion Euro threshold. To guide investment decisions and to safeguard maximum medical benefit and safety for patients recruited in clinical trials, it is therefore essential to understand the clinical consequences of all information and data generated. The complexity of the physiological and pathophysiological processes and the sheer amount of information available overcharge the mental capacity of any human being and prevent a prediction of the success in clinical development. A rigorous integration of knowledge, assumption, and experimental data into computational models promises a significant improvement of the rationalization of decision making in pharmaceutical industry. We here give an overview of the current status of modeling and simulation in pharmaceutical R&D and outline the perspectives of more recent developments in mechanistic modeling. Specific modeling approaches for different biological scales ranging from intracellular processes to whole organism physiology are introduced and an example for integrative multiscale modeling of therapeutic efficiency in clinical oncology trials is showcased.Keywords
This publication has 44 references indexed in Scilit:
- Towards whole‐body systems physiologyMolecular Systems Biology, 2010
- HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiologyMolecular Systems Biology, 2010
- Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regenerationProceedings of the National Academy of Sciences, 2010
- Who will take up the gauntlet?EMBO Reports, 2009
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsThe Pharmacogenomics Journal, 2009
- Predicting metabolic biomarkers of human inborn errors of metabolismMolecular Systems Biology, 2009
- Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coliMolecular Systems Biology, 2007
- Global reconstruction of the human metabolic network based on genomic and bibliomic dataProceedings of the National Academy of Sciences, 2007
- The model organism as a system: integrating 'omics' data setsNature Reviews Molecular Cell Biology, 2006
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003